• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Jim Cramer

Jim Cramer: Looking for Gold? Go With Science

A potential breakthrough in Alzheimer's. A new device for blood pressure. More vaccines. These are opportunities to cheer in a time of turmoil.
By JIM CRAMER
Jan 12, 2021 | 03:46 PM EST
Stocks quotes in this article: JPM, LLY, PFE, MDT, BMY

Science ... is golden. You just don't hear about it.

That's how I feel about this terrific JPMorgan (JPM) Healthcare conference, the one that is totally overshadowed by events in Washington and the storming of the Capitol.

We live in a suspect time; the truth is obscured, events are subject to interpretation -- after they occurred -- so-called post-truth, and the cynicism is so thick that it coats everything with toxic waste.

But some things are objective and are not subject to interpretation, things like the victories we are hearing about from CEOs of health care companies that are addressing a sophisticated audience of investors.

Let's start with Eli Lilly's (LLY) drug that has been shown to slow the onset of Alzheimer's in recently symptomatic patients, long the failed dream of so many pharmaceutical companies. In an admittedly small phase 2 trial, Lilly tested a monoclonal antibody that slowed patients' decline in cognition and daily function by 32% relative to a placebo. Within about a year and half, the data showed the plaques that are associated with Alzheimer's were significantly reduced in most patients.

That's stunning. I believe if the Republic weren't in danger of cratering, this story would have led the New York Times. Two column banner. Instead there was a squib about it that was shorter than an article about the New York Jets losing still one more game.

About 50 million people worldwide have dementia, with 10 million new people diagnosed each year. Alzheimer's causes about 60% to 70% of those stricken with dementia.

I know many major pharmaceutical drug execs, both current and past, who have spent billions trying to get these results and have had to give up in frustration. Everything has failed. Few companies are even attempting to beat this disease even as it is one of the biggest unmet needs out there.

Science was golden.

How about vaccines? All we hear about is the clown show of vaccine distributions with 50 states coordinating 50 different ways of distributing the vaccines. No federal plan for getting the needle into your arm because the President decided to burden the states, which have no idea what they are doing and no budget to do so.

Pfizer (PFE) , however, upped its production numbers. Looks like it can produce two billion vaccines. If our vaccine administration weren't so godawful, we would be cheering the science of coming up with that many vaccines.

Instead, nobody cares, because it will probably end up on a bunch of shelves somewhere and then go bad. A miracle squandered.

How about Medtronic (MDT) ? It's got a new device that can possibly knock out hypertension, a leading cause of death. It can monitor it and tell you how you can keep your blood pressure at the perfect level. There's never been anything like it and no one I know has ever thought it would be possible. Too many false positives. Too many things that go wrong. No more.

Nobody cared.

Bristol-Myers Squibb  (BMY) announced it is applying for a new drug that could basically save the lives of people with heart failure. It's a huge market.

The market's saying, so what?

I could go on and on.

Fortunately, there are enough professional investors who are profiting from it. Unfortunately, in a time of national gloom, these breakthroughs are ignored by the media and positives go unnoticed.

At least here they don't. Science is indeed golden, but I won't let it be silent anymore. We need something to cheer about. Eureka, I think I have found it.

(JPM and BMY and are holdings in Jim Cramer's Action Alerts PLUS member club. Want to be alerted before Jim Cramer buys or sells these stocks? Learn more now.)

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Jim Cramer's Action Alerts PLUS member club is long JPM and BMY.

TAGS: Drug Approvals | Stocks | Jim Cramer | Health |

More from Jim Cramer

Jim Cramer: This GameStop Nonsense Has Gotten Out of Hand

Jim Cramer
Feb 26, 2021 7:11 AM EST

It has become the market equivalent of the storming of the Capitol, and the viciousness must stop.

Jim Cramer: The Bond Market Vigilantes Strike

Jim Cramer
Feb 25, 2021 1:41 PM EST

What does that mean for stocks? Consider Nvidia.

Jim Cramer: How Do You Pull Off What GameStop Buyers Did?

Jim Cramer
Feb 25, 2021 6:12 AM EST

Here's my theory on how this was done.

Jim Cramer: Don't Miss This Train

Jim Cramer
Feb 22, 2021 2:40 PM EST

We're headed to Boom Town, so let me show you how to line up your ticket -- and the best picks for the great reopening.

Jim Cramer: Toast, the Next Big Thing? I Question its Valuation

Jim Cramer
Feb 22, 2021 6:19 AM EST

Maybe it will be viewed as the ultimate 'opening' story because restaurants might soon come back.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:32 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Navigating a Market Correction
  • 11:29 AM EST GARY BERMAN

    Where Does the Nasdaq Go From Here?

    Where does the Nasdaq Composite (CCMP) index go fr...
  • 12:31 PM EST GARY BERMAN

    Has the Short-Term Top Come for the XLF/Banks?

    The has triggered a long-term overbought signal ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login